Last reviewed · How we verify

ALRN-6924 in combination with cytarabine

Aileron Therapeutics, Inc. · Phase 1 active Small molecule

ALRN-6924 in combination with cytarabine is a Small molecule drug developed by Aileron Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: ALRN-6924 in combination with Ara-C.

At a glance

Generic nameALRN-6924 in combination with cytarabine
Also known asALRN-6924 in combination with Ara-C
SponsorAileron Therapeutics, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ALRN-6924 in combination with cytarabine

What is ALRN-6924 in combination with cytarabine?

ALRN-6924 in combination with cytarabine is a Small molecule drug developed by Aileron Therapeutics, Inc..

Who makes ALRN-6924 in combination with cytarabine?

ALRN-6924 in combination with cytarabine is developed by Aileron Therapeutics, Inc. (see full Aileron Therapeutics, Inc. pipeline at /company/aileron-therapeutics-inc).

Is ALRN-6924 in combination with cytarabine also known as anything else?

ALRN-6924 in combination with cytarabine is also known as ALRN-6924 in combination with Ara-C.

What development phase is ALRN-6924 in combination with cytarabine in?

ALRN-6924 in combination with cytarabine is in Phase 1.

Related